Phase II study of seliciclib in patients with previously treated advanced nasopharyngeal cancer.
Phase of Trial: Phase II
Latest Information Update: 29 May 2009
At a glance
- Drugs Seliciclib (Primary)
- Indications Nasopharyngeal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cyclacel Pharmaceuticals
- 29 May 2009 Safety results from 23 patients in the lead-in part of the study have been reported at ASCO 2009. The trial will now proceed into the second part of the study; reported in a Cyclacel media release.
- 08 Nov 2007 Recruitment is expected to start by the end of 2007.
- 08 Feb 2007 New trial record.